Evidence map›Paper›PMID 38688589›Full record

ArticleIn vivo (Athens, Greece)

Extensive Shrinkage and Long-term Stable Disease in a Teenage Female Patient With High-grade Glioma Treated With Temozolomide and Radiation in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.

Motokazu Sato, Qinghong Han, Kohei Mizuta, Ryosuke Mori, Byung Mo Kang, Sei Morinaga, Noritoshi Kobayashi, Yasushi Ichikawa, Atsushi Nakajima, Robert M Hoffman

Abstract readCase Reports
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Recombinant Expression of L-methioninase fromProtein and peptide letters · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Motokazu SatoAntiCancer Inc., San Diego, CA, U.S.A.
Qinghong HanAntiCancer Inc., San Diego, CA, U.S.A.
Kohei MizutaAntiCancer Inc., San Diego, CA, U.S.A.
Ryosuke MoriAntiCancer Inc., San Diego, CA, U.S.A.
Byung Mo KangAntiCancer Inc., San Diego, CA, U.S.A.
Sei MorinagaAntiCancer Inc., San Diego, CA, U.S.A.
Noritoshi KobayashiDepartment of Oncology, Yokohama City University School of Medicine, Yokohama, Japan.
Yasushi IchikawaDepartment of Oncology, Yokohama City University School of Medicine, Yokohama, Japan.
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Robert M HoffmanAntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimGliomas are the most common and recalcitrant malignant primary brain tumors. All cancer types are addicted to methionine, which is a fundamental and general hallmark of cancer known as the Hoffman effect. Particularly glioma cells exhibit methionine addiction. Because of methionine addiction, [ CASE REPORT: A 16-year-old girl was diagnosed with high-grade glioma. Magnetic resonance imaging (MRI) showed a left temporal-lobe tumor with compression to the left lateral ventricle and narrowing of sulci in the left temporal lobe. After the start of methionine restriction with o-rMETase and a low-methionine diet, along with TMZ combined with radiotherapy, the tumor size shrunk at least 60%, with improvement in the left lateral ventricle and sulci. The patient's condition remains stable for 19 months without severe adverse effects.

conclusionMethionine restriction consisting of o-rMETase and a low-methionine diet, in combination with radiation and TMZ as first-line chemotherapy, were highly effective in a patient with high-grade glioma.

Indexed as

Carbon-Sulfur LyasesGliomaMethionineTemozolomideAdolescentBrain NeoplasmsCombined Modality TherapyFemaleHumansMagnetic Resonance ImagingNeoplasm GradingPositron-Emission TomographyRecombinant ProteinsTreatment OutcomeCarbon-Sulfur LyasesL-methionine gamma-lyaseMethionineRecombinant ProteinsTemozolomidecombination therapyHigh-grade gliomaHoffman effectlow-methionine dietmethionine addictionmethionine restrictionoral methioninaseradiationsynergytemozolomide

Identifiers

PMID38688589
PMCPMC11059867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.